Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


The Bull Case For ResMed (RMD) Could Change Following U.S. Probe Into Medical Device Imports

2025-09-29
Earlier this month, the U.S. Commerce Department initiated a national security investigation into medical device imports, including those produced by major manufacturers such as ResMed, raising the possibility of tariffs and regulatory changes for the industry. This move has introduced fresh uncertainty around supply chains and costs, particularly for companies with significant U.S. market exposure and global manufacturing operations. We'll explore how the U.S. investigation into imported...

Align Technology, ResMed, Insulet, Envista, and Dentsply Sirona Shares Plummet, What You Need To Know

2025-09-25
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.

Zacks.com featured highlights include GE Aerospace, ResMed, Vertiv and National Fuel Gas

2025-09-25
GE Aerospace, ResMed, Vertiv, and National Fuel Gas emerge as Zacks GARP picks, blending growth prospects with value appeal.

Anesthesia and Respiratory Devices Global Markets Report 2025-2030, Profiles of Prominent Players - F. Hoffmann-La Roche, Koninklijke Philips, ResMed, Teleflex, GE Healthcare, and Medtronic

2025-09-25
Key market opportunities in anesthesia and respiratory devices include technological advancements, regulatory developments, and growing demand for patient monitoring, ventilators, and disposable products. Companies can leverage innovations in ESG practices and sustainability trends to gain a competitive edge in expanding global markets. Anesthesia and Respiratory Devices Market Anesthesia and Respiratory Devices Market Dublin, Sept. 25, 2025 (GLOBE NEWSWIRE) -- The "Anesthesia and Respiratory De

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

2025-09-24
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, RMD, VRT and NFG are some such stocks.

ResMed's (NYSE:RMD) investors will be pleased with their respectable 66% return over the last five years

2025-09-24
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...

ResMed Inc. (RMD) Presents at Bank of America Global Healthcare Conference 2025 Transcript

2025-09-23
ResMed Inc. (NYSE:RMD) Bank of America Global Healthcare Conference 2025 September 23, 2025 8:20 AM EDTCompany ParticipantsMichael Farrell - CEO &...

Health Care Roundup: Market Talk

2025-09-19
Health Care Roundup: Market Talk

Baxter Stock Slips Despite Latest Launch to Boost Patient Monitoring

2025-09-18
BAX launches FDA-cleared Connex 360 monitor, aiming to boost frontline care and streamline patient monitoring.

Citigroup Initiates Coverage of ResMed (RMD) with Buy Recommendation

2025-09-18